Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India

J Clin Lipidol. 2023 Mar-Apr;17(2):e1-e14. doi: 10.1016/j.jacl.2022.11.002. Epub 2022 Nov 23.

Abstract

In 2021 an estimated 74 million individuals had diabetes in India, almost all type 2 diabetes. More than half of patients with diabetes are estimated to be undiagnosed and more 90% have dyslipidemia that is associated with accelerated development of atherosclerotic cardiovascular disease (ASCVD). Patients of Indian descent with diabetes have multiple features that distinguish them from patients with diabetes in Western populations. These include characteristics such as earlier age of onset, higher frequency of features of the metabolic syndrome, more prevalent risk factors for ASCVD, and more aggressive course of ASCVD complications. In light of the unique features of diabetes and diabetic dyslipidemia in individuals of Indian descent, the Lipid Association of India developed this expert consensus statement to provide guidance for management of diabetic dyslipidemia in this very high risk population. The recommendations contained herein are the outgrowth of a series of 165 webinars conducted by the Lipid Association of India across the country from May 2020 to July 2021, involving 155 experts in endocrinology and cardiology and an additional 2880 physicians.

Keywords: Cardiovascular prevention; Diabetes; Diabetic dyslipidemia; Expert consensus; Treatment.

MeSH terms

  • Atherosclerosis* / complications
  • Atherosclerosis* / therapy
  • Cardiology*
  • Cardiovascular Diseases*
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / epidemiology
  • Dyslipidemias* / complications
  • Dyslipidemias* / epidemiology
  • Dyslipidemias* / therapy
  • Humans
  • India / epidemiology
  • Lipids
  • Risk Factors

Substances

  • Lipids